Search

Your search keyword '"N. V. Zarechnova"' showing total 9 results
Start Over Author "N. V. Zarechnova" Topic humans
9 results on '"N. V. Zarechnova"'

1. Analysis of influence of background therapy for comorbidities in the period before infection on the risk of the lethal COVID outcome. Data from the international ACTIV SARS-CoV-2 registry («Analysis of chronic non-infectious diseases dynamics after COVID-19 infection in adult patients SARS-CoV-2»)

Author

N V Lareva, A Sh Kerimova, D A Shсukarev, I. V. Fomin, I. A. Karetnikov, K. F. Kasymova, U. K. Kamilova, A. M. Budu, A O Konradi, A. A. Marusina, V. I. Majseenko, Yu D Zimina, E. V. Ponomarenko, E. V. Grigorieva, N. V. Bakulina, I. G. Pochinka, O. V. Kondriakova, N. A. Lyubavina, A. G. Sushilova, K. V. Protasov, E A Konstantinova, Yu. M. Lopatin, I I Shaposhnik, O. V. Karpov, I. A. Soloveva, N. V. Zarechnova, M. V. Bragin, G. T. Aimakhanova, O Yu Badina, O Yu Chizhova, A. P. Rebrov, D. V. Soloveva, E S Kim, V. I. Levankova, S. V. Malchikova, A. S. Galyavich, I. M. Sukhomlinova, M. B. Cholponbaeva, A. V. Klimova, A. R. Vaisberg, M. P. Konoval, V. V. Skachkova, N. N. Vezikova, E. A. Gаlova, N. A. Prokofeva, M Е Levin, L. A. Balykova, M. V. Kazakovtseva, A. S. Makarova, T. I. Chudinovskikh, K R Vagapova, A. K. Subbotin, N Yu Kurchugina, A. T. Tursunova, L. D. Petrov, O. R. Aruslanova, M V Ilina, Yu N Belenkov, I. V. Gubareva, E. S. Melnikov, G. A. Bykova, S Yu Ivanova, Yu V Titojkina, Z. F. Kim, A. V. Aparkina, D Yu Konstantinov, A. M. Maripov, K. V. Trenogina, Ch K. Kulchoroeva, E. A. Yausheva, S. S. Plastinina, N. D. Ulanova, D. D. Varlamova, E. V. Makarova, S. V. Nedogoda, R. V. Gostishev, A. P. Babin, A S Sarybaev, S. A. Avetisian, M. S. Torgunakova, G P Arutyunov, O. V. Fedorishina, L. V. Kurenkova, Sh O. Ospanova, G M Dabylova, E. I. Gorshenina, V V Genkel, N. M. Nikitina, M Kh Karsiev, R. G. Muradyan, M. V. Boldina, S Yu Sherbakov, A. A. Odegova, E. P. Tikhonova, M. I. Kolyadich, D. N. Protsenko, V. V. Gomonova, N. A. Karoli, T. V. Kuprina, N. B. Moiseenko, A O Myshak, K Yu Shishkov, N Yu Grigorieva, K. E. Egorova, A. N. Rakhimov, V. A. Pogrebetskaya, S. N. Tereshchenko, V. V. Vustina, I. U. Bikhteyev, N. A. Magdeyeva, Sh N. Musaelian, A. A. Tulichev, O. V. Khlynova, E. V. Kolmakova, A. I. Demchenko, E. V. Pahomova, I. A. Frolova, D. A. Trofimov, M. Y. Duyshobayev, A I Chesnikova, T. S. Fil, A. S. Kuznetsova, N. A. Kamardina, K. V. Kuzmichev, I. V. Demko, D. A. Klimenko, D. S. Evdokimov, O. E. Vilkova, K. V. Mazalov, A Ch Akunov, A. N. Ermilova, N. A. Rakov, B. B. Ogurlieva, O. V. Fatenkov, O. A. Shevchenko, A A Tolmacheva, E Yu Ashina, E. A. Vinnikova, D Yu Ruzanau, Zh B. Kerimbekova, A. K. Abdrahmanova, Yu S. Kalinina, T. V. Sheshina, I. G. Bakulin, Yu M. Omarova, A. V. Zharkov, I S Fominova, H. G. Hayrapetyan, L. A. Burygina, N. V. Kiseleva, A. M. Karachenova, A. M. Bitieva, D. S. Polyakov, T V Kriukova, F. M. Sokhova, A. G. Arutyunov, D. A. Ayipova, M. M. Petrova, M K Alieva, N. A. Borodulina, F. N. Muradova, I. A. Pudova, N A Kushubakova, A. A. Simonov, V. V. Tsoma, S. Serikbolkyzy, O Yu Barisheva, E. A. Shishkina, O. V. Kovalishena, L. L. Popova, A. V. Evzerikhina, A S Batchayeva, T Yu Kuzmina, K. K. Azarian, D. S. Tokmin, N. A. Omurzakova, D S Кaskaeva, A. E. Zheldybayeva, T. Yu. Kuznetsova, I Yu Fomina, E. A. Verbitskaya, N. A. Rozanova, D. R. Tagayeva, S. M. Tsvinger, E. Yu. Ivanchenko, S A Sayganov, N. A. Trostianetckaia, A. S. Blagonravova, A. Yu. Kraposhina, V. A. Kordukova, E. I. Tarlovskaya, O Yu Dolgikh, I. M. Kouranova, H. G. Avoyan, E. V. Kazymova, T. P. Kolchinskaya, N M Selezneva, A. B. Sugraliev, E. V. Koroleva, and E Yu Gubareva

Subjects
Adult, Male, medicine.medical_specialty, Population, Disease, Comorbidity, Lower risk, Pharmacotherapy, Internal medicine, medicine, Humans, Registries, education, Noncommunicable Diseases, Pandemics, education.field_of_study, COPD, business.industry, SARS-CoV-2, COVID-19, medicine.disease, Clopidogrel, Diabetes Mellitus, Type 2, Female, Cardiology and Cardiovascular Medicine, business, Ticagrelor, medicine.drug
Abstract

Aim To study the effect of regular drug therapy for cardiovascular and other diseases preceding the COVID-19 infection on severity and outcome of COVID-19 based on data of the ACTIVE (Analysis of dynamics of Comorbidities in paTIents who surVived SARS-CoV-2 infEction) registry.Material and methods The ACTIVE registry was created at the initiative of the Eurasian Association of Therapists. The registry includes 5 808 male and female patients diagnosed with COVID-19 treated in a hospital or at home with a due protection of patients’ privacy (data of nasal and throat smears; antibody titer; typical CT imaging features). The register territory included 7 countries: the Russian Federation, the Republic of Armenia, the Republic of Belarus, the Republic of Kazakhstan, the Kyrgyz Republic, the Republic of Moldova, and the Republic of Uzbekistan. The registry design: a closed, multicenter registry with two nonoverlapping arms (outpatient arm and in-patient arm). The registry scheduled 6 visits, 3 in-person visits during the acute period and 3 virtual visits (telephone calls) at 3, 6, and 12 mos. Patient enrollment started on June 29, 2020 and was completed on October 29, 2020. The registry completion is scheduled for October 29, 2022. The registry ID: ClinicalTrials.gov: NCT04492384. In this fragment of the study of registry data, the work group analyzed the effect of therapy for comorbidities at baseline on severity and outcomes of the novel coronavirus infection. The study population included only the patients who took their medicines on a regular basis while the comparison population consisted of noncompliant patients (irregular drug intake or not taking drugs at all despite indications for the treatment).ResultsThe analysis of the ACTIVE registry database included 5808 patients. The vast majority of patients with COVID-19 had comorbidities with prevalence of cardiovascular diseases. Medicines used for the treatment of COVID-19 comorbidities influenced the course of the infectious disease in different ways. A lower risk of fatal outcome was associated with the statin treatment in patients with ischemic heart disease (IHD); with angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor antagonists and with beta-blockers in patients with IHD, arterial hypertension, chronic heart failure (CHF), and atrial fibrillation; with oral anticoagulants (OAC), primarily direct OAC, clopidogrel/prasugrel/ticagrelor in patients with IHD; with oral antihyperglycemic therapy in patients with type 2 diabetes mellitus (DM); and with long-acting insulins in patients with type 1 DM. A higher risk of fatal outcome was associated with the spironolactone treatment in patients with CHF and with inhaled corticosteroids (iCS) in patients with chronic obstructive pulmonary disease (COPD).Conclusion In the epoch of COVID-19 pandemic, a lower risk of severe course of the coronavirus infection was observed for patients with chronic noninfectious comorbidities highly compliant with the base treatment of the comorbidity.

Published
2021

2. [International register 'Analysis of Chronic Non-infectious Diseases Dynamics After COVID-19 Infection in Adult Patients (ACTIV SARS-CoV-2)']

Author

V. V. Tsoma, N A Krivosheina, M S Grigorovich, D. R. Tagayeva, D Y Ruzanau, A. M. Budu, A O Konradi, I Y Fomina, E. V. Kazymova, O. V. Kondriakova, I I Shaposhnik, M D Gaukhar, E. V. Grigorieva, N. N. Vezikova, I A Duvanov, I. A. Pudova, N. A. Prokofeva, G. T. Aimakhanova, D. A. Trofimov, E. S. Melnikov, L. D. Shakhgildyan, T. I. Chudinovskikh, M. V. Kazakovtseva, A. T. Tursunova, A. K. Abdrahmanova, A. B. Sugraliev, E. V. Koroleva, A. P. Rebrov, D. S. Evdokimov, S V Baramzina, E. P. Tikhonova, N. A. Magdeyeva, Y N Belenkov, T. Y. Kuzmina, A A Levchenko, L. A. Burygina, S T Fil, A S Kerimova, I. M. Kouranova, A. R. Vaisberg, M. P. Konoval, Z. F. Kim, A. V. Aparkina, A. A. Tulichev, D. S. Tokmin, I. V. Fomin, S. N. Tereshchenko, N. U. Grigorieva, D V Saphonov, N. A. Kamardina, R. V. Gostishev, U. K. Kamilova, L. A. Smirnova, O A Chumakova, H. G. Avoyan, N A Kushubakova, K. V. Mazalov, A. N. Ermilova, V V Genkel, N. A. Lyubavina, A E Gаlova, O. V. Fatenkov, Y M Lopatin, V. V. Gomonova, H. G. Hayrapetyan, N. V. Zarechnova, E S Kim, Z D Rasulova, N Y Kurchugina, S A Sayganov, N. M. Nikitina, T. V. Sheshina, G P Arutyunov, V. I. Levankova, S. V. Malchikova, A. A. Simonov, T. V. Kuprina, E Y Ashina, S. S. Plastinina, A S Sarybaev, N. A. Trostianetckaia, I. A. Frolova, S. V. Nedogoda, S. Serikbolkyzy, F. N. Muradova, M. B. Cholponbaeva, A. V. Evzerikhina, N. A. Rozanova, T Y Kuznetsova, A. S. Galyavich, A. A. Odegova, A C Akunov, D. I. Tupitsin, Y V Omarova, A. S. Blagonravova, A. K. Subbotin, O Y Barisheva, N. V. Kiseleva, A. V. Klimova, Sh O. Ospanova, M. E. Levin, M. Y. Duyshobayev, O. V. Kovalishena, V M Boldina, E. V. Makarova, Zh B. Kerimbekova, E Y Gubareva, D. V. Soloveva, D. N. Protsenko, N. A. Karoli, K. E. Egorova, A Y Kraposhina, V. A. Pogrebetskaya, K. K. Azarian, E. V. Pahomova, N V Zelyaeva, D. A. Ayipova, S. A. Avetisian, O Y Badina, R. G. Muradyan, I. V. Demko, V. A. Kordukova, E. I. Tarlovskaya, D Y Konstantinov, M. I. Kolyadich, A. E. Zheldybayeva, A. P. Babin, Sh N. Musaelian, D S Kaskaeva, S Y Chukhlova, K Y Shishkov, T. P. Kolchinskaya, T V Kriukova, I. V. Gubareva, O Y Dolgikh, V. I. Majseenko, O. V. Karpov, I. A. Soloveva, S Y Sherbakov, A. M. Bitieva, D. S. Polyakov, E M Mamutova, F. M. Sokhova, A. G. Arutyunov, L. D. Petrov, M. M. Petrova, S Y Ivanova, D. D. Varlamova, A. A. Tiurin, D A Doshchannikov, A. I. Demchenko, A I Chesnikova, A. S. Kuznetsova, D. A. Klimenko, and O. E. Vilkova

Subjects
Adult, 2019-20 coronavirus outbreak, Adult patients, Coronavirus disease 2019 (COVID-19), business.industry, SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), MEDLINE, COVID-19, Virology, Medicine, Humans, Cardiology and Cardiovascular Medicine, business, Noncommunicable Diseases, Non infectious
Published
2021

3. [Surgical treatment of the pulmonary embolism]

Author

V E, Zagaĭnov, A P, Medvedev, S A, Aĭvaz'ian, A A, Seregin, V V, Pichugin, V A, Bel'skiĭ, N V, Zarechnova, and A I, Zaĭtsev

Subjects
Echocardiography, Angiography, Humans, Female, Embolectomy, Pulmonary Embolism, Aged, Follow-Up Studies
Published
2013

4. [Effect of antihypoxant infusion on microbial endotoxin circulation in obstructive jaundice patients]

Author

A Ia, Iakovlev, A A, Niazmatov, N V, Zarechnova, R R, Zaĭtsev, N V, Emel'ianov, K V, Mokrov, and A S, Chichkanova

Subjects
Lipopolysaccharides, Kupffer Cells, Succinates, Endotoxemia, Ringer's Solution, Jaundice, Obstructive, Glucose, Liver, Cholelithiasis, Fluid Therapy, Humans, Infusions, Parenteral, Isotonic Solutions, Organic Chemicals, Gram-Negative Bacterial Infections
Abstract

The dynamics of microbial endotoxemia in group of 149 patients with cholelithiasis complicated by obstructive jaundice has been studied as dependent on the perioperative tactics of infusion therapy. The perioperative period in obstructive jaundice patients is complicated by a significant increase in lipopolysaccharidemia caused by translocation mechanisms and disorders of the liver detoxification function. In Group 1, 47 patients received infusion therapy including Ringer's solution and 10% glucose solution at a 1:1 ratio. In group 2, 55 patients received infusion therapy with only Sterofundin G-5 solution. In Group 3, 47 patients received the infusion therapy with remaxol in a dose of 800 ml/day. It is established that the infusion of Sterofundin G-5, and to a greater extent the infusion of remaxol, reduces the early postoperative degree of decompensation and accelerates recovery of the detoxifying function of Kupffer cells with respect to microbial endotoxin.

Published
2013

5. [Infusion correction of bile outflow and endotoxicosis in patients with mechanical jaundice]

Author

A Iu, Iakovlev, V B, Semenov, N V, Emel'ianov, K V, Mokrov, P S, Zubeev, S V, Akulenko, and N V, Zarechnova

Subjects
Male, Bilirubin, Succinates, Ringer's Solution, Drug Combinations, Jaundice, Obstructive, Glucose, Treatment Outcome, Liver, Preoperative Care, Bile, Humans, Female, Isotonic Solutions, Organic Chemicals, Infusions, Intravenous
Abstract

The investigations were performed in 139 patients divided into 3 groups and who were given similar volume of infusion therapy (1600 ml/day). In the first group consisting of 54 patients the solution of infusion therapy included the Ringer solution and 10% of glucose solution in the ratio 1:1. In the second group (37 patients) the infusion therapy was performed with a solution of sterofundin-G-5. In the third group (48 patients) remaksol in dose 800 ml/day was included in infusion therapy. The inclusion of sterofundin-G-5 and remaksol in the infusion therapy increased the rate of bile outflow at the early postoperative period as compared with the solutions of Ringer and 10% of glucose. Remaksol is better for arresting endotoxicosis and bile excreting function of the liver as compared with infusion of sterofundin-G-5.

Published
2012

6. [Tactics of preoperative infusion therapy in obturation jaundice]

Author

A Iu, Iakovlev, V B, Semenov, N V, Emel'ianov, K V, Mokrov, S V, Akulenko, and N V, Zarechnova

Subjects
Jaundice, Obstructive, Treatment Outcome, Liver Function Tests, Cholelithiasis, Preoperative Care, Drainage, Humans, Cholecystectomy, Infusions, Parenteral, Prospective Studies, Ultrasonography
Abstract

The influence of the infusion therapy content on a hepatic function of bile outflow (HFBO), a bilirubin content and the enzymes activity in obturation jaundice in 139 patients was studied up. In 54 patients (the first group) a Ringer solution and 10% solution of glucose in 1:1 ratio were applied; in 37 patients (the second group) - a sterofundin-G-5 solution; in 48 patients (the third group) - remaxol in a dose of 800 ml/day. Application of sterofundin-G-5 and remaxol as a component of infusion therapy have promoted a bile outflow intensity enhancement in early postoperative period in comparison with such while Ringer solution and 10% solution of glucose application. Remaxol more effectively have eliminated a hyperbilirubinemia, enzymemia and a HFBO disorder, than sterofundin-G-5.

Published
2012

7. [Surgical treatment of colorectal cancer liver metastases with microwave thermoablation]

Author

V E, Zagaĭnov, G G, Gorokhov, N V, Zarechnova, P I, Rykhtik, S A, Vasenin, M A, Sudakov, A V, Kostrov, and A V, Strikovskiĭ

Subjects
Liver Neoplasms, Humans, Colorectal Neoplasms, Microwaves, Retrospective Studies
Abstract

Domestic device for destruction of tumors by microwave power was designed. Initial series of laboratory experiments were performed with microwave liver ablation. Primary series of patients with colorectal cancer metastases to the liver demonstrate positive results. Short-term exposure, programmable shapes and sizes of ablative zones are the distinctive advantages of microwave thermoablation (MTA). 329 patients underwent liver resections during 2005-2010 years.108 patients had colorectal cancer metastases to the liver. 52 (48,14%) patients had bilobar liver lesions. Among them 11 patients underwent liver resection combined with MTA of contralateral liver lesions. Reliable differences in survival rates among patients with monolobar and bilobar metastatic lesions were not observed. Median of survival rate amounted 22.8 months in patients operated for metastatic colorectal cancer. Variants of surgical treatment are proposed.

Published
2011

8. [Infusion therapy in patients with cholelithiasis complicated by obstructive jaundice]

Author

A Iu, Iakovlev, V B, Semenov, R M, Zaĭtsev, N G, Smirnova, N V, Emel'ianov, A G, Zakharov, S V, Akulenko, and N V, Zarechnova

Subjects
Jaundice, Obstructive, Treatment Outcome, Cholelithiasis, Preoperative Care, Humans, Succinates, Prospective Studies, Isotonic Solutions, Infusions, Intravenous, Follow-Up Studies, Ringer's Solution
Published
2011

Catalog

Books, media, physical & digital resources
See catalog results